Diadema Partners’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.09M Buy
254,863
+61,674
+32% +$1.82M 1.02% 27
2026
Q1
$5.82M Buy
193,189
+122,889
+175% +$3.98M 0.99% 35
2025
Q4
$2.44M Sell
70,300
-54,084
-43% -$1.91M 0.42% 53
2025
Q3
$4.52M Buy
124,384
+20,000
+19% +$679K 1.16% 31
2025
Q2
$3.28M Buy
104,384
+7,400
+8% +$230K 1% 33
2025
Q1
$2.88M Buy
+96,984
New +$2.91M 0.75% 32

Other funds holding IMCR

Diadema Partners's IMCR Position: Q2 2026 in Review

Diadema Partners increased its Immunocore (IMCR) stake by 32% in Q2 2026, buying an estimated $1.82M and bringing the position to 254,863 shares worth $8.09M. The position accounts for 1.02% of the portfolio, ranked #27.

Diadema Partners first reported a position in IMCR in Q1 2025 and has held it in 6 quarters since. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Diadema Partners held 254,863 shares of Immunocore worth $8.09M as of Q2 2026.
  • Diadema Partners bought 61,674 Immunocore shares in Q2 2026, an estimated $1.82M.
  • Immunocore made up 1.02% of Diadema Partners's portfolio in Q2 2026, its #27 holding.
  • Diadema Partners first reported a position in Immunocore in Q1 2025 and has held it in 6 quarters since.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.